SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a complete response letter for Summits ivonescimab application, saying the survival evidence did not meet its standard for approval despite a strong progression-free-survival result. Traders are reacting with frustration and debating whether the FDAs overall-survival requirement was unusually strict or Summit filed too early, while some remain optimistic about the drugs longer-term prospects.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff and volatile rebound are driving discussion, with traders citing leveraged liquidations and spot ETF outflows while debating whether oversold conditions signal a bottom or only a temporary bounce before further declines.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is drawing attention over the nationwide FAA communications outage, with officials pointing to its network equipment while investigators determine whether a router defect or installation error was responsible; a cyberattack remains unconfirmed. Traders are split between expecting legal and contract fallout and arguing the company is being made a scapegoat, with some viewing the selloff as a buying opportunity.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 8.82035932 USD and is down -10.43 over the last 24 hours. It is currently trading on 2316 active market(s) with $423,389,171.98 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINK is drawing attention amid volatile price action, with dip-buyers betting on its institutional infrastructure and tokenization adoption while skeptics argue that partnerships and usage have not translated into sustained token gains. Traders are also debating whether recent weakness is a buying opportunity or another sign of underperformance.

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,079,921,637.950731 in circulation. The last known price of Algorand is 0.07697008 USD and is down -9.60 over the last 24 hours. It is currently trading on 586 active market(s) with $68,192,697.70 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGO is drawing attention amid persistent weakness near multi-year lows, with traders split over whether the price is forming support or remains vulnerable to further declines. Bulls describe the weakness as an accumulation opportunity and point to Algorands post-quantum technology and tokenization potential, while bears question demand and adoption and warn that rebounds may not signal a lasting recovery.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Attention centers on Sareptas awaited DM1 and FSHD multiple-dose readouts, seen by bullish traders as a test of its siRNA pipeline. PepGens reported DM1 results have raised the efficacy bar, adding to debate between optimism about a potential catalyst and concern that Sareptas data may disappoint amid prolonged weak trading.

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Attention centers on the December 17 FDA decision for relacorilant in Cushings syndrome, resubmitted with additional analyses requested by the agency after a prior rejection. Traders are divided on approval prospects and regulatory risk; the debate is sharpened by CORTs sharp pullback despite a strong Q3 report, with some also questioning unchanged revenue guidance.

Evernorth Holdings Inc. engages in acquiring and actively managing XRP assets through public equity markets. Its activities include efficient XRP acquisition, active portfolio management, yield-generation strategies involving traditional and decentralized finance opportunities, and geographic expansion focused initially on Japan and South Korea. The company was founded in August 29, 2025 and is headquartered in San Francisco, CA.

Evernorth Holdings Inc. - Ordinary Shares - Class A

Evernorth Holdings Inc.

Evernorths sharp retreat after its post-merger spike has traders focused on potential selling pressure from resale filings and warrant-related share supply. Weak XRP prices add to the bearish debate, while some investors see the pullback as an opportunity and others criticize the SPAC and crypto-treasury structure.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Investor Day discussion is centered on Praxis launch preparations for ulixacaltamide in essential tremor and relutrigine in rare epilepsies, alongside the pending FDA decisions and broader EMERALD trial data. Traders largely welcome the commercial plans and market opportunity, while some question the ambitious uptake and pricing assumptions and remain cautious about regulatory timing.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers Q3 results are drawing attention after revenue and adjusted earnings beat estimates and the company raised its full-year revenue outlook, while lowering its adjusted EPS guidance partly because of licensing-related charges. Traders are weighing the strong results against the guidance cut and ongoing concerns about replacing revenue as older drugs face patent pressure.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
